Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  DBV Technologies    DBV   FR0010417345

DBV TECHNOLOGIES (DBV)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
33.1(c) 32.16(c) 31.34(c) 30.92(c) 30.2 Last
46 246 62 329 74 667 80 051 61 227 Volume
-1.31% -2.84% -2.55% -1.34% -2.33% Change
More quotes
Financials (EUR)
Sales 2018 7,33 M
EBIT 2018 -182 M
Net income 2018 -175 M
Finance 2018 157 M
Yield 2018 -
Sales 2019 44,2 M
EBIT 2019 -156 M
Net income 2019 -178 M
Debt 2019 26,2 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 107x
EV / Sales2019 22,0x
Capitalization 944 M
More Financials
Company
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products.It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient,... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of DBV Technologies
Trading Rating : Investor Rating :
More Ratings
Latest news on DBV TECHNOLOGIES
07/14DBV TECHNOLOGIES : Half-Year Report on the DBV Technologies Liquidity Contract a..
AQ
07/13DBV TECHNOLOGIES : Half-Year Report on the DBV Technologies Liquidity Contract a..
PU
07/13DBV TECHNOLOGIES : Half-Year Report on the DBV Technologies Liquidity Contract a..
GL
07/13DBV TECHNOLOGIES : Half-Year Report on the DBV Technologies Liquidity Contract a..
AQ
06/22DBV TECHNOLOGIES : Announces Results of its 2018 Ordinary and Extraordinary Gene..
GL
06/22DBV TECHNOLOGIES : Proxy Statments
CO
06/21DBV TECHNOLOGIES : Monthly statement on outstanding equity shares and voting rig..
CO
06/05DBV TECHNOLOGIES : to Attend Upcoming Investor Conferences
GL
06/05DBV TECHNOLOGIES : to Attend Upcoming Investor Conferences
AQ
06/01DBV TECHNOLOGIES : Ordinary and Extraordinary General Meeting of June 22, 2018 -..
GL
More news
Sector news : Diagnostic & Testing Substances Manufacturers
05:44pCanadian cannabis company Tilray surges in Nasdaq debut
RE
03:19pBarclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
02:37pNovartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
12:19pFinance Chiefs Say Too Much Data Is Making It Harder to Keep on Top of Risks
DJ
11:55aBarclays appoints Campili as vice chairman for healthcare banking
RE
More sector news : Diagnostic & Testing Substances Manufacturers
Latest Tweets
07:20aDBV Technologies $DBVT Stock Rating Upgraded by Zacks Investment Research  
07/18DBV Technologies $DBVT Upgraded to Hold by Zacks Investment Research  
07/17$DBV Technologies $DBVT pipeline & milestones (June) - still waiting for .. 
07/13DBV Technologies : Half-Year Report on the DBV Technologies Liquidity Contrac.. 
07/04Head to Head Survey: DBV Technologies $DBVT versus La Jolla Pharmaceutical $L.. 
More tweets
Qtime:43
News from SeekingAlpha
03/23DBV closes $173M equity offering 
03/14DBV Technologies, Boulogne-Billancourt reports FY results 
03/06YOUR DAILY PHARMA SCOOP : Aimmune Data, Onconova Shares Get A Boost, G1 Therapeu.. 
03/04AIMMUNE THERAPEUTICS : Insider Buying Alert 
02/27U.S. BIOTECH/PHARMA SECTOR DAILY OBS : February 26, 2018 
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | DBV | FR0010417345 | 4-Traders
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 77,2 €
Spread / Average Target 150%
EPS Revisions
Managers
NameTitle
Pierre-Henri Benhamou Chairman & Chief Executive Officer
Charles Ruban Chief Operating Officer
Bertrand Dupont Chief Technology Officer
Lucia Septién Chief Medical Officer
Hugh A. Sampson Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
DBV TECHNOLOGIES-26.20%1 094
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225